Gallbladder Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Gallbladder Treatment Market Trends and Insights

Rising Gallstone and Biliary Disease Burden

Gallbladder and biliary disease caused 73.2 million new cases globally in 2021, compared with 45.7 million cases in 1990, with population growth and aging accounting for much of the increase.^{[1]“Global Burden of Gallbladder and Biliary Diseases (1990–2021): A Systematic Analysis,”} Global prevalence is projected to rise 27.3% by 2035, while deaths are projected to increase from 136,221 to 186,486, extending demand beyond high-income care systems. South America had a gallstone prevalence of 11.2%, compared with the 6.1% global average, and Chile and Bolivia had among the highest gallbladder cancer mortality rates.^{[2]“Burden and Risk Factors for Gallbladder and Biliary Tract Diseases,”} Western Sub-Saharan Africa was the only region where DALY rates and mortality rates both increased between 1990 and 2021, pointing to substantial unmet access to laparoscopic treatment. Patients in lower-income settings may reach care later, and the mortality concentration index increased from 0.24 in 1990 to 0.31 in 2021. The gallbladder treatment market needs practical laparoscopic capacity, timely imaging, and providers that can combine emergency surgery with biliary endoscopy, because disease growth does not guarantee treatment access.

Preference for Minimally Invasive Cholecystectomy

Laparoscopic cholecystectomy remains the central surgical approach for most gallstone cases, while robotic surgery is being adopted at tertiary centers with sufficient capital and training. A study of 23,513 patients found a 0.65% bile duct injury rate with robotic cholecystectomy, compared with 1.02% with laparoscopic procedures, with fewer conversions to open surgery, shorter stays, and lower 30-day readmission and mortality. In December 2025, the U.S. Food and Drug Administration cleared Intuitive Surgical’s da Vinci SP system for cholecystectomy, extending single-incision robotic access to abdominal procedures. The gallbladder treatment market is developing along 2 paths, with tertiary centers using robotic platforms and other hospitals relying on laparoscopic instruments. Standard multiport instruments face pricing pressure where robotic systems are established, while single-use laparoscopic disposables remain relevant where robots are not financially feasible. This split makes clinical outcomes, operating time, case volume, devices, training, and service contracts important in hospital purchasing decisions.

Aging, Obesity, Diabetes, and Metabolic Risk Clustering

Aging, obesity, diabetes, and related metabolic conditions can increase the clinical burden behind the gallbladder treatment market. The global analysis attributed 95.37% of the increase in gallbladder-related deaths to population aging, while obesity and metabolic syndrome support cholesterol gallstone formation through hepatic cholesterol hypersecretion. A cohort study found that 3 years of GLP-1 receptor agonist use was associated with a 1.64-times higher risk of cholelithiasis than matched controls. The study also reported 1.95-times higher adjusted odds of cholecystectomy, with a 95% confidence interval of 1.31 to 2.88. These risks can increase the number of patients needing imaging, monitoring, and surgical consultation, while metabolic medicines may improve disease control and add biliary risk for some patients. Providers with coordinated gastroenterology, endocrine, and surgical pathways may be better placed to manage these cases.

Fluorescence and Decision-Support Tools Improving Bile-Duct Visualization

Indocyanine green fluorescence cholangiography is becoming an important safety tool in complex cholecystectomies. A meta-analysis of 14 studies involving 3,576 patients found that ICG-assisted procedures reduced postoperative complications from 7.25% to 4.78% and bile leakage from 2.02% to 0.43%, with a relative risk of 0.27.^{[3]“Effects of Indocyanine Green Imaging-Assisted Cholecystectomy on Intraoperative and Postoperative Complications: A Meta-Analysis,”} In acute cholecystitis, fluorescence guidance was associated with a 1.2% conversion rate, compared with 3.3% in the control group, and lower odds of bailout procedures, at 0.05.^{[4]“Surgical Outcomes of ICG Fluorescence-Guided Laparoscopic Cholecystectomy in Acute Cholecystitis,”} Fluorescence imaging can support minimally invasive treatment by helping surgeons identify biliary anatomy. Some robotic systems include this capability, and the gallbladder treatment market may benefit when safety evidence supports payer confidence and combined workflow training. Its effect is strongest at hospitals with advanced imaging and specialized teams, while smaller hospitals may continue to prioritize basic laparoscopy because access and cost are more immediate needs.

High Procedure, Equipment, and Skilled-Workforce Costs

Robotic cholecystectomy costs USD 5,000 to USD 6,000 per procedure in Western centers, while laparoscopic surgery costs USD 2,000 to USD 3,000. Disposable costs averaged USD 1,309 for a robotic case and USD 534 for a laparoscopic case in a multicenter analysis. The difference limits access where public reimbursement sets procedure prices, including Brazil’s SUS and India’s PMJAY. Workforce shortages also limit same-day care because anesthesiology capacity and robotic training are required. Device companies use consumable agreements and training subsidies, but these measures do not remove the basic cost gap. Secondary hospitals may be unable to justify robotic certification or the procedure volume it requires, so equipment makers need choices suited to tertiary and lower-cost settings. The gallbladder treatment market can expand access only when diagnostic capacity is matched by trained staff and operating capacity across APAC, South America, the Middle East, and Africa.

Bile-Duct Injury, Infection, Leakage, and Postcholecystectomy Risks

Procedure risk remains an important limit on treatment choices, even as visualization and surgical technique improve. Laparoscopic cholecystectomy had a 1.02% bile duct injury rate in the cited Mayo Clinic Enterprise analysis, while persistent pain, functional diarrhea, and dyspepsia can create follow-up demand. For ERCP-based bile duct clearance, 70.9% of procedures achieved stone clearance in the first session. Repeat ERCP was needed by 22.8% of patients, and the overall complication rate was 4.8%, including pancreatitis in 1.7% and biliary sepsis in 1.5%. These outcomes affect payer assessments and limit movement to lower-acuity settings, making clinical selection and complication management essential for patients with comorbidities. The gallbladder treatment market depends on matching the setting to patient risk, and the 2025 World Endoscopy Organization guidance supports wire-guided cannulation and post-ERCP pancreatitis risk assessment. 

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Disease Indication: Gallstones Dominate, Gallbladder Cancer Accelerates

Gallstones held 63.47% of the gallbladder treatment market share within disease-indication revenue in 2025. The position reflects their prevalence and their role as the main clinical reason for cholecystectomy. Gallstones affect an estimated 10% to 20% of adults in Western populations. Germany performed 175,000 cholecystectomies annually, with 90% conducted laparoscopically. France performed 57,568 reimbursed cholecystectomies in 2025, and more than 90% used laparoscopy. Acute cholecystitis and biliary colic add a significant emergency-care workload to the high volume of elective gallstone treatment.

Biliary dyskinesia and postcholecystectomy syndrome are receiving more clinical attention as non-stone motility conditions. They are particularly relevant for female patients and people who have undergone metabolic surgery. Gallbladder cancer is the fastest-growing indication, at a 9.23% CAGR from 2026 to 2031. The FDA granted accelerated approval to zanidatamab-hrii in November 2024 for previously treated HER2-positive biliary tract cancer. The approval was supported by a 52% objective response rate and a 14.9-month median duration of response. In May 2026, the FDA approved zenocutuzumab-zbco for NRG1 fusion-positive cholangiocarcinoma, adding a targeted option for this molecular subtype. 

By Diagnosis and Treatment: Treatment Anchors Share, Diagnosis Closes the Gap

Treatment accounted for 62.79% of revenue in 2025, giving it the largest position in this gallbladder treatment industry segmentation. Diagnosis is the fastest-growing category and is projected to grow at a 9.92% CAGR from 2026 to 2031. Ultrasound remains the main initial imaging method because it is accessible and relatively low-cost. MRCP and ERCP are gaining use in complex, oncologic, and choledocholithiasis presentations. ERCP achieved primary biliary cannulation in 93.5% of procedures at experienced centers. First-session stone clearance reached 70.9%, which supports the use of advanced cholangioscopy, laser lithotripsy, and balloon dilation when standard treatment is insufficient.

The diagnosis portion of the gallbladder treatment market is supported by protocols that improve procedure planning and risk assessment. The World Endoscopy Organization issued ERCP guidelines in June 2025 that support consistent cannulation and sphincterotomy practice. Laparoscopic cholecystectomy remains the dominant treatment by surgical volume, while open surgery remains necessary for complicated cases, adhesions, and constrained settings. Ursodeoxycholic acid remains a non-surgical option for selected patients with small radiolucent cholesterol stones and preserved gallbladder function. Antibiotics and supportive medicines remain central to acute cholecystitis management. Single-stage ERCP with laparoscopic cholecystectomy has shown higher stone clearance and lower pancreatitis than sequential 2-step care in published meta-analyses.

By End User: Hospitals Lead as Gynecology Clinics Emerge as a Growth Pocket

Hospitals held 56.32% of end-user revenue in 2025 because they can support advanced surgical suites, robotic platforms, and multidisciplinary biliary teams. Their facilities also manage acute presentations that require urgent cholecystectomy. Academic and research centers contribute a high proportion of clinical trial enrollment and investigational device adoption. Their role is important even when their direct treatment revenue is lower than that of hospitals. North American and European hospitals have led the adoption of robotic cholecystectomy. The supplied research also reported 12% year-over-year growth in Intuitive Surgical's global da Vinci installed base.

Gynecology clinics are projected to grow at an 11.47% CAGR through 2031. Female incident cases reached 47.8 million in 2021 and outnumbered male incident cases by 1.9 to 1 globally. The category is supported by the integration of biliary care within women’s health service lines. The other category includes ambulatory surgery centers and standalone outpatient clinics. It is expanding as reimbursement changes in the United States and similar policies in Western Europe encourage care outside hospital outpatient departments. This shift gives the gallbladder treatment market more routes to deliver lower-acuity procedural care. It also changes how suppliers approach customers, because hospitals, research centers, clinics, and outpatient facilities have different requirements for staffing, imaging access, operating-room design, and recurring instruments.

Geography Analysis

North America held 38.62% of the gallbladder treatment market share in 2025. The gallbladder treatment market in the region benefits from a dense ambulatory surgery center network and an advanced base of minimally invasive surgical capability. Changes to the ambulatory surgery center covered procedure list support a wider range of biliary and gastrointestinal care settings. Canada is expanding day-case laparoscopic pathways through provincial health systems. Mexico’s private hospital network is increasing diagnostic and laparoscopic capacity in major urban centers. These conditions support procedure throughput, but hospital and payer requirements continue to determine which patients can safely use ambulatory care.

Asia-Pacific is the fastest-growing region, with a projected 12.49% CAGR from 2026 to 2031. The gallbladder treatment market in the region contains large untapped treatment volumes and uneven access to minimally invasive procedures. Guangdong Province General Hospital is using 3D and 4K fluorescence laparoscopy, 1.9 mm laparoscopic instruments, and 2.8 mm choledochoscopes for combined single-port cholecystectomy and bile duct stone extraction. The hospital reports that this pathway can support same-day discharge for procedures that earlier required 1-week inpatient stays. India represents a large volume opportunity because gallstone prevalence is estimated at 4% across a population of 1.4 billion. Japan, Australia, South Korea, and India are at different stages of adoption, so product design and pricing must vary across the region.

Europe has a significant gallbladder treatment market size because Germany, France, the United Kingdom, Italy, and Spain have established surgical systems. Germany’s annual 175,000 cholecystectomies and 90% laparoscopic rate demonstrate the scale of mature procedural care. Western Europe had the highest global prevalence rate of gallbladder and biliary disease, at 4,009.85 per 100,000 people. Brazil recorded more than 1.5 million hospitalizations for cholelithiasis and cholecystitis from 2020 to 2024. In the Middle East and Africa, Saudi Arabia and the UAE are adding tertiary capacity, while Western Sub-Saharan Africa has rising disease burden and limited treatment access.